{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:36:44Z","timestamp":1790282204807,"version":"4.1.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2007,11,13]]},"abstract":"<jats:p><jats:bold><jats:italic>Background\u2014<\/jats:italic><\/jats:bold>It is unclear whether abnormalities of arginine and nitric oxide metabolism are related to hemodynamic dysfunction and mortality in patients with cardiogenic shock (CS) after acute myocardial infarction.<\/jats:p><jats:p><jats:bold><jats:italic>Methods and Results\u2014<\/jats:italic><\/jats:bold>Plasma metabolites reflecting arginine bioavailability, nitric oxide metabolism, and protein oxidation were analyzed by mass spectrometry in patients with CS (n=79) and age- and gender-matched patients with coronary artery disease and normal left ventricular function (n=79). CS patients had higher levels of asymmetric dimethylarginine (ADMA;<jats:italic>P<\/jats:italic>&lt;0.0001), symmetric dimethylarginine (<jats:italic>P<\/jats:italic>&lt;0.0001), monomethylarginine (<jats:italic>P<\/jats:italic>=0.0003), nitrotyrosine (<jats:italic>P<\/jats:italic>&lt;0.0001), and bromotyrosine (<jats:italic>P<\/jats:italic>&lt;0.0001) and lower levels of arginine (<jats:italic>P<\/jats:italic>&lt;0.0001), ratio of arginine to ornithine (<jats:italic>P<\/jats:italic>=0.03), and ratio of arginine to ornithine plus citrulline) (<jats:italic>P<\/jats:italic>=0.0003). CS patients with elevated ADMA levels were 3.5-fold (95% confidence interval, 1.4 to 11.3;<jats:italic>P<\/jats:italic>=0.02) more likely to die in 30 days than patients with low ADMA levels. ADMA remained the only independent predictor of mortality on multiple logistic regression analysis. In patients with normal renal function, symmetric dimethylarginine levels inversely correlated with mean arterial pressure and systemic vascular resistance, whereas levels of ADMA correlated with pulmonary capillary wedge pressure and both systolic and diastolic pulmonary artery pressures. Despite dramatic elevations, levels of protein oxidation products did not predict hemodynamic dysfunction or mortality in CS patients.<\/jats:p><jats:p><jats:bold><jats:italic>Conclusions\u2014<\/jats:italic><\/jats:bold>CS is characterized by an arginine-deficient and highly specific pro-oxidant state, with elevated levels of methylated arginine derivatives, including endogenous nitric oxide synthase inhibitors. Levels of methylated arginine derivatives strongly correlate with hemodynamic dysfunction. Among all clinical and laboratory parameters monitored, ADMA levels were the strongest independent predictor of 30-day mortality.<\/jats:p>","DOI":"10.1161\/circulationaha.107.693986","type":"journal-article","created":{"date-parts":[[2007,10,29]],"date-time":"2007-10-29T23:19:55Z","timestamp":1193699995000},"page":"2315-2324","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":89,"title":["Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction"],"prefix":"10.1161","volume":"116","author":[{"given":"Stephen J.","family":"Nicholls","sequence":"first","affiliation":[{"name":"From the Department of Cardiovascular Medicine (S.J.N., S.E.N., S.L.H.) and Center for Cardiovascular Diagnostics and Prevention (S.J.N., Z.W., R.K., B.L., B.D., S.L.H.), Cleveland Clinic Foundation, Cleveland Ohio; Interventional Cardiology Program, Toronto General Hospital, Toronto, Canada (V.D.); Arginox Pharmaceuticals, Redwood City, Calif (O.W.G., D.H.); Coronary Care Unit, Washington Hospital Center, Washington, DC (J.A.P.); and Cardiovascular Clinical Research Center, New York University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeneng","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Department of Cardiovascular Medicine (S.J.N., S.E.N., S.L.H.) and Center for Cardiovascular Diagnostics and Prevention (S.J.N., Z.W., R.K., B.L., B.D., S.L.H.), Cleveland Clinic Foundation, Cleveland Ohio; Interventional Cardiology Program, Toronto General Hospital, Toronto, Canada (V.D.); Arginox Pharmaceuticals, Redwood City, Calif (O.W.G., D.H.); Coronary Care Unit, Washington Hospital Center, Washington, DC (J.A.P.); and Cardiovascular Clinical Research Center, New York University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Koeth","sequence":"additional","affiliation":[{"name":"From the Department of Cardiovascular Medicine (S.J.N., S.E.N., S.L.H.) and Center for Cardiovascular Diagnostics and Prevention (S.J.N., Z.W., R.K., B.L., B.D., S.L.H.), Cleveland Clinic Foundation, Cleveland Ohio; Interventional Cardiology Program, Toronto General Hospital, Toronto, Canada (V.D.); Arginox Pharmaceuticals, Redwood City, Calif (O.W.G., D.H.); Coronary Care Unit, Washington Hospital Center, Washington, DC (J.A.P.); and Cardiovascular Clinical Research Center, New York University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Levison","sequence":"additional","affiliation":[{"name":"From the Department of Cardiovascular Medicine (S.J.N., S.E.N., S.L.H.) and Center for Cardiovascular Diagnostics and Prevention (S.J.N., Z.W., R.K., B.L., B.D., S.L.H.), Cleveland Clinic Foundation, Cleveland Ohio; Interventional Cardiology Program, Toronto General Hospital, Toronto, Canada (V.D.); Arginox Pharmaceuticals, Redwood City, Calif (O.W.G., D.H.); Coronary Care Unit, Washington Hospital Center, Washington, DC (J.A.P.); and Cardiovascular Clinical Research Center, New York University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"DelFraino","sequence":"additional","affiliation":[{"name":"From the Department of Cardiovascular Medicine (S.J.N., S.E.N., S.L.H.) and Center for Cardiovascular Diagnostics and Prevention (S.J.N., Z.W., R.K., B.L., B.D., S.L.H.), Cleveland Clinic Foundation, Cleveland Ohio; Interventional Cardiology Program, Toronto General Hospital, Toronto, Canada (V.D.); Arginox Pharmaceuticals, Redwood City, Calif (O.W.G., D.H.); Coronary Care Unit, Washington Hospital Center, Washington, DC (J.A.P.); and Cardiovascular Clinical Research Center, New York University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Dzavik","sequence":"additional","affiliation":[{"name":"From the Department of Cardiovascular Medicine (S.J.N., S.E.N., S.L.H.) and Center for Cardiovascular Diagnostics and Prevention (S.J.N., Z.W., R.K., B.L., B.D., S.L.H.), Cleveland Clinic Foundation, Cleveland Ohio; Interventional Cardiology Program, Toronto General Hospital, Toronto, Canada (V.D.); Arginox Pharmaceuticals, Redwood City, Calif (O.W.G., D.H.); Coronary Care Unit, Washington Hospital Center, Washington, DC (J.A.P.); and Cardiovascular Clinical Research Center, New York University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen W.","family":"Griffith","sequence":"additional","affiliation":[{"name":"From the Department of Cardiovascular Medicine (S.J.N., S.E.N., S.L.H.) and Center for Cardiovascular Diagnostics and Prevention (S.J.N., Z.W., R.K., B.L., B.D., S.L.H.), Cleveland Clinic Foundation, Cleveland Ohio; Interventional Cardiology Program, Toronto General Hospital, Toronto, Canada (V.D.); Arginox Pharmaceuticals, Redwood City, Calif (O.W.G., D.H.); Coronary Care Unit, Washington Hospital Center, Washington, DC (J.A.P.); and Cardiovascular Clinical Research Center, New York University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hathaway","sequence":"additional","affiliation":[{"name":"From the Department of Cardiovascular Medicine (S.J.N., S.E.N., S.L.H.) and Center for Cardiovascular Diagnostics and Prevention (S.J.N., Z.W., R.K., B.L., B.D., S.L.H.), Cleveland Clinic Foundation, Cleveland Ohio; Interventional Cardiology Program, Toronto General Hospital, Toronto, Canada (V.D.); Arginox Pharmaceuticals, Redwood City, Calif (O.W.G., D.H.); Coronary Care Unit, Washington Hospital Center, Washington, DC (J.A.P.); and Cardiovascular Clinical Research Center, New York University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio A.","family":"Panza","sequence":"additional","affiliation":[{"name":"From the Department of Cardiovascular Medicine (S.J.N., S.E.N., S.L.H.) and Center for Cardiovascular Diagnostics and Prevention (S.J.N., Z.W., R.K., B.L., B.D., S.L.H.), Cleveland Clinic Foundation, Cleveland Ohio; Interventional Cardiology Program, Toronto General Hospital, Toronto, Canada (V.D.); Arginox Pharmaceuticals, Redwood City, Calif (O.W.G., D.H.); Coronary Care Unit, Washington Hospital Center, Washington, DC (J.A.P.); and Cardiovascular Clinical Research Center, New York University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[{"name":"From the Department of Cardiovascular Medicine (S.J.N., S.E.N., S.L.H.) and Center for Cardiovascular Diagnostics and Prevention (S.J.N., Z.W., R.K., B.L., B.D., S.L.H.), Cleveland Clinic Foundation, Cleveland Ohio; Interventional Cardiology Program, Toronto General Hospital, Toronto, Canada (V.D.); Arginox Pharmaceuticals, Redwood City, Calif (O.W.G., D.H.); Coronary Care Unit, Washington Hospital Center, Washington, DC (J.A.P.); and Cardiovascular Clinical Research Center, New York University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith S.","family":"Hochman","sequence":"additional","affiliation":[{"name":"From the Department of Cardiovascular Medicine (S.J.N., S.E.N., S.L.H.) and Center for Cardiovascular Diagnostics and Prevention (S.J.N., Z.W., R.K., B.L., B.D., S.L.H.), Cleveland Clinic Foundation, Cleveland Ohio; Interventional Cardiology Program, Toronto General Hospital, Toronto, Canada (V.D.); Arginox Pharmaceuticals, Redwood City, Calif (O.W.G., D.H.); Coronary Care Unit, Washington Hospital Center, Washington, DC (J.A.P.); and Cardiovascular Clinical Research Center, New York University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley L.","family":"Hazen","sequence":"additional","affiliation":[{"name":"From the Department of Cardiovascular Medicine (S.J.N., S.E.N., S.L.H.) and Center for Cardiovascular Diagnostics and Prevention (S.J.N., Z.W., R.K., B.L., B.D., S.L.H.), Cleveland Clinic Foundation, Cleveland Ohio; Interventional Cardiology Program, Toronto General Hospital, Toronto, Canada (V.D.); Arginox Pharmaceuticals, Redwood City, Calif (O.W.G., D.H.); Coronary Care Unit, Washington Hospital Center, Washington, DC (J.A.P.); and Cardiovascular Clinical Research Center, New York University..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02173-3"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908263410901"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.2.190"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000075927.67673.f2"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ph.57.030195.003423"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1253\/jcj.65.827"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0022-3565(24)36716-3","volume":"281","year":"1997","unstructured":"Flesch M, Kilter H, Cremers B, Lenz O, Sudkamp M, Kuhn-Regnier F, Bohm M. Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. J Pharmacol Exp Ther. 1997; 281: 1340\u20131349.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.93.6.1223"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ph.57.030195.004011"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(91)90636-5"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.89.5.7514109"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.101.12.1358"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(03)00193-3"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi980742t"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.3169"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.0000128897.54893.26"},{"key":"e_1_3_2_17_2","first-page":"1949.","volume":"110","year":"2004","unstructured":"Dzavik V, Cotter G, Farkouh ME, Ramanathan K, Reynolds HR, Baran D, Cantor W, Menon V, Kaluski E, Prondzinsky R, Stebbins A, Alexander J, Hochman JS. Effect of nitric oxide synthase inhibition on hemodynamics and outcome of patients with acute myocardial infarction complicated by cardiogenic shock: a phase 2 dose-ranging study. Circulation. 2004; 110: 1949. Abstract.","journal-title":"Circulation"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm075"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(05)96022-9"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200421109"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112400200"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-2317fje"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019501-199907000-00002"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/1358836X0000500108"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118632"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/134.10.2807S"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.1.58"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199704000-00009"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(75)90078-9"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200309-1304OC"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-002-2563-2"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.1.81"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01400-0"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/atvb.20.6.1557"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.98.18.1842"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs1000161"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199715080-00015"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.99.9.1141"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890500472151"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(98)70437-5"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(97)00242-3"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-003-0715-y"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(98)00225-2"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200104000-00016"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200308000-00006"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.29.1.242"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000085067.55901.89"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1161\/atvb.20.4.1040"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.0000136656.26019.6e"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1042\/CS103S241S"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.69.221"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000046489.24563.79"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj1540179"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)81786-0"},{"key":"e_1_3_2_55_2","first-page":"4960","volume":"63","year":"2003","unstructured":"Kostourou V, Robinson SP, Whitley GS, Griffiths JR. Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. Cancer Res. 2003; 63: 4960\u20134966.","journal-title":"Cancer Res"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(03)01507-9"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000101924.04515.2e"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.212269799"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc5053"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.15.joc70035"},{"key":"e_1_3_2_61_2","first-page":"972","volume":"298","year":"2007","unstructured":"Harrington RA, Alexander JH, Hochman JS, Reynolds HR, Dzavik V, Van de Werf FJ. Tilarginine in patients with acute myocardial infarction and cardiogenic shock. JAMA. 2007; 298: 972\u2013973.","journal-title":"JAMA"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.107.693986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:38:28Z","timestamp":1737506308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.107.693986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,13]]},"references-count":61,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2007,11,13]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.107.693986"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.107.693986","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,13]]},"assertion":[{"value":"2007-10-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}